LONGi Green Energy Technology (601012.SH) won the bid for the largest domestic centralized BC project totaling 3.71 billion yuan, using second-generation BC technology with a conversion efficiency of 24.43%.
Longi Green Energy Technology Co., Ltd. (601012.SH) issued an announcement that its wholly-owned subsidiary Longi Top World Photovoltaic Technology Co., Ltd. (abbreviated...
LONGi Green Energy Technology (601012.SH) announced that its wholly-owned subsidiary, Longi Leye Photovoltaic Technology Co., Ltd. (referred to as "Longi Leye"), has received a notification of being awarded a project. With the leading advantage of BC second-generation technology, Longi Leye successfully won the bid for the largest domestic centralized BC project.
The awarded projects include the "A Power Goes to Wuhai" regional mutual assistance new energy project (1.7 million kilowatts of photovoltaics), Inner Mongolia Energy Group Dalad Qi Sand control and sand treatment 500,000 kilowatt photovoltaic integration phase one project, and Inner Mongolia Energy Group Hangjin Qi Sand control and sand treatment 1.1 million kilowatt wind-solar integration project photovoltaic component equipment procurement (Section Three: Inner Mongolia Energy Group Dalad Qi Sand control and sand treatment 500,000 kilowatt photovoltaic integration phase one project 500,000 kilowatts). The total bid amount is 371 million yuan.
It is reported that this bid-winning project is the largest single centralized BC project in the country. The project will use the company's self-developed BC second-generation technology component products, with a maximum power of 660W and a corresponding conversion efficiency of 24.43%, resulting in higher electricity generation under the same area. This project win showcases the important breakthrough of the company's BC second-generation technology in the market of centralized photovoltaic power stations in desertified areas, demonstrating the advantages of BC second-generation technology in all scenarios.
Related Articles

STANCHART (02888) plans to issue $1 billion fixed rate reset perpetual callable convertible securities.

HUTCHMED (00013) announces the completion of patient recruitment for the SAFFRON global Phase III study of the combination therapy of sulfasalazine and terizsa for specific lung cancer patients with MET overexpression and/or amplification after treatment with terizsa.

ASCLETIS-B (01672) will report on the complete analysis of the Phase Ib study of ASC30 oral tablets at ObesityWeek in 2025, as well as the Phase Ib study of ASC30 injection, and preclinical studies on the combination therapy of ASC31 and ASC47.
STANCHART (02888) plans to issue $1 billion fixed rate reset perpetual callable convertible securities.

HUTCHMED (00013) announces the completion of patient recruitment for the SAFFRON global Phase III study of the combination therapy of sulfasalazine and terizsa for specific lung cancer patients with MET overexpression and/or amplification after treatment with terizsa.

ASCLETIS-B (01672) will report on the complete analysis of the Phase Ib study of ASC30 oral tablets at ObesityWeek in 2025, as well as the Phase Ib study of ASC30 injection, and preclinical studies on the combination therapy of ASC31 and ASC47.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


